SMOORE
23.9.2021 13:17:15 CEST | Business Wire | Press release
SMOORE, a global leader in offering vaping technology solutions, today has made its mark at The Global Tobacco & Nicotine Forum (GTNF) 2021. Senior Vice President of SMOORE and President of FEELM, the flagship atomization tech brand belonging to SMOORE, Frank Han makes the keynote speech to outline SMOORE’s mission of “atomization making life better.”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210923005511/en/
The Global Tobacco & Nicotine Forum (GTNF) is the world’s leading annual forum discussing the future of the tobacco and nicotine industries. The annual industry conference brings together key stakeholders from around the world, including global tobacco companies, vaping brands, scientists, public health experts, NGOs and policymakers.
In his speech, Frank Han calls upon all stakeholders of the industry to join the mission of “atomization making life better”, promoting the evolution of atomization ecosystem . He asserts that policymakers and NGOs should take the lead in institutional innovations to promote the healthier industry development and more balanced regulations, embracing vaping as a strategy to improve public health while safeguarding against youth vaping. Global media could also involve more people in the unbiased public dialogue on vaping.
Moreover, industry leaders should work together to build up more comprehensive industry standards. As one of the key industry standard setters, SMOORE has developed its vapor and material safety standards, which involve over 300 physical and chemical tests. These standards have also covered all of PMTA tests and the safety evaluation of over 50 atomization materials, thereby guaranteeing industry-leading product quality.
In terms of product innovation , Frank Han indicates that the underlying technology of vaping—atomization, has showed promising prospects in other fields, such as healthcare. With one of its R&D focus on the atomization application in healthcare, SMOORE has made significant progress on the research of atomized medication in the past three years.
“In the near future, more and more people will inhale medicines or vaccines with atomization devices. It could help the world pull through the pandemic,” said Frank Han.
According to Frank Han, SMOORE’s innovations are based on its insights into global consumers’ requirements and the commitment to improving user experience, which is the company’s first principle of product development. Based on the principle, SMOORE launched the world’s first Taste Evaluation Model in 2020, covering 4 dimensions and 51 indexes, so as to establish a scientific system to evaluate vaping tastes.
Moreover, Frank Han points out that scientific innovation is the driving force of the industry’s evolution. Industry pioneers are constantly committed to the cross-disciplinary fundamental research of “atomization science”, to explore the mechanism of atomization.
As the world’s leading atomization tech platform, SMOORE has recruited R&D experts from different backgrounds and built up 7 global research centers around the world. In addition to in-house R&D resources, SMOORE has partnered with top universities to leverage the latest scientific discoveries and transform them into cutting–edge applied technologies.
The industry is also embracing intelligent manufacturing to improve resource efficiency. For example, SMOORE introduced the first fully automated pod production line in the world. Now, a single line of SMOORE can produce 7,200 standard vaporizers per hour.
In partnership with clients, SMOORE has also adopted sustainable practices in all stages of product development, especially manufacturing, so as to fulfill its commitment to reducing carbon footprint.
“Innovation and sustainability are the ideas to which the whole industry has been adhering, since the advent of vaping. The two ideas share a common goal, that is ‘atomization making life better’, which echoes SMOORE’s corporate mission,” said Frank Han.
Committed to the mission of “Atomization making life better”, SMOORE will continue to discover more diversified atomization methods and more advanced technology roadmap while jointly promoting a more inclusive dialogue mechanism along with partners from different sectors.
About SMOORE
SMOORE is a global leader in offering vaping technology solutions, including manufacturing vaping devices, and vaping components, with advanced R&D technology, strong manufacturing capacity, wide-spectrum product portfolio and diverse customer base. The Company is the world's largest vaping device manufacturer in terms of revenue, accounting for 18.9% of the total global market share.
About FEELM
FEELM is a high-end atomization technology brand belonging to SMOORE. Focusing on the research of cutting-edge atomization technology, FEELM also specializes in the development and manufacturing of high quality atomization devices driven by FEELM ceramic coil. “FEELM inside” symbol is on the closed system pods of a number of global leading tobacco companies and vaping companies around the world. The accumulated sales volume of FEELM has surpassed 3 billion pieces per year.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210923005511/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom